Usefulness of cell-mediated immune function in risk stratification for patients with advanced heart failure
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Nagarajan, VijaiganeshHernandez, Adrian V.
Cauthen, Clay A.
Starling, Randall C.
Tang, W. H. Wilson
Issue Date
2017-01Keywords
Acetylsalicylic acidAngiotensin receptor antagonist
Beta adrenergic receptor blocking agent
Clopidogrel
Dipeptidyl carboxypeptidase inhibitor
Hydralazine
nitric acid derivative
Phytohemagglutinin
Spironolactone
xmlui.metadata.dc.contributor.email
tangw@ccf.org
Metadata
Show full item recordCitation
Usefulness of cell-mediated immune function in risk stratification for patients with advanced heart failure 2017, 183:35 American Heart JournalPublisher
Mosby Inc.Journal
American Heart JournalDOI
10.1016/j.ahj.2016.09.008Additional Links
http://linkinghub.elsevier.com/retrieve/pii/S0002870316302046Abstract
Although heightened inflammation and autoimmune responses have been well described in patients with heart failure, the role of cell-mediated immune function in the pathogenesis and progression of heart failure is unclear. The aim of our study is to evaluate the prognostic role of cell-mediated immune function in patients with advanced heart failure. Methods We studied patients with advanced heart failure referred for evaluation of candidacy for advanced heart failure therapies between 2007 and 2010. Cell-mediated immune response was categorized into 3 groups—low or poor immune response (≤225 ng/mL), moderate or normal immune response (226-524 ng/mL), and strong immune response (≥525 ng/mL)—using a phytohemagglutinin-stimulated T-cell response assay. Results Out of 368 patients, 41 patients (11.1%) had poor immune function, 258 patients (70.1%) had normal immune function, and 69 patients (18.7%) had strong immune function. The primary outcome of all-cause mortality or cardiac transplantation occurred in 63.4%, 45.3%, and 34.8% in the poor immunity, normal immunity, and strong immune function groups, respectively. In univariate analysis, cell-mediated immune function was strongly associated with the primary outcome (P =.014). Poor immune function portended worse prognosis (hazard ratio = 2.18, 95% CI 1.01-4.70, P =.047), and strong immune function was associated with better survival (hazard ratio = 0.67, 95% CI 0.43-1.04). However, when adjusted for multiple variables in multivariate analysis, immune function status lost its overall significance to predict primary outcome (P = 0.11), but the direction to an increased risk of primary outcome was maintained in the poor immune function group. Conclusions Poor cell-mediated immune function measured by a clinically available assay could be associated with more adverse long-term prognosis in patients with advanced heart failure. © 2016 Elsevier Inc.Type
info:eu-repo/semantics/articleRights
info:eu-repo/semantics/restrictedAccessLanguage
engDescription
El texto completo de este trabajo no está disponible en el Repositorio Académico UPC por restricciones de la casa editorial donde ha sido publicado.ISSN
00028703ae974a485f413a2113503eed53cd6c53
10.1016/j.ahj.2016.09.008
Scopus Count
Collections